Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Transcript
You've looked at real-world outcomes in patients with newly diagnosed multiple myeloma. How do your findings compare with previous research?
In this study we were looking at the outcomes of RVd [lenalidomide plus bortezomib and dexamethasone] versus Vd [bortezomib and dexamethasone] in real-world patients that were treated. And what was interesting is that in the overall population, the progression-free survival was improved with the triplet RVd by 26 months, but what we also were able to do in this, because it’s a real-world study, is look at subgroups, such as patients over the age of 80, and they benefitted equally.
With all of these subgroups I’m about to mention, all had more than a 20-month benefit. So, patients that were over age 80, Charlson Comorbidity Index more than 2, and also ECOG performance status of 2 or higher. So, often these 3 groups of patients are not included in studies, so you really don’t know what are the data. How many 80-year-old plus are included in a clinical trial? Almost none. So, it’s good to see that this triplet therapy in real world also still contributed to improved clinical outcomes with triplet therapy.
I would say, though, I think it’s important to use dose attenuation with these regimens to make sure that patients are tolerating them well. But clearly dose-attenuated RVd can be very well tolerated and is associated with excellent outcomes.
What is the importance of looking at real-world outcomes?
I think in general, we’re learning more and more that clinical trials are really important to get drugs approved, but we really do need to balance that with real-world evidence, recognizing all the disparities between the 2. And I think this is not just unique to myeloma, but in all of oncology, the clinical trial selection criteria are sometimes so rigid we really need to broaden them. And particularly for myeloma, where our patients are older, they’re going to have other cancers, they’re going to have renal dysfunction. If we’re not allowing these patients, how do we generalize study data to who we’re actually treating in the clinic?
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More
More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.
Read More